Peer-reviewedPublisher termsmBio
Corticosteroids drive oral candidiasis by impairing type-17 immunity without inducing interferon-gammopathy
- 1Fungal Pathogenesis Section, Laboratory of Clinical Immunology and Microbiology, National Institutes of Health, National Institute of Allergy and Infectious Diseases
- 2Postdoctoral Research Associate Program, National Institute of General Medical Sciences, National Institutes of Health
Related
- Interferon-λ inhibits immunopathology and boosts T cell–mediated immunity in a mouse model of mucosal viral infection
- Early dynamics of a neutrophil interferon program drive immunotherapy resistance and limit durable anti-tumor immunity
- Interferon regulatory factor 3 beyond innate immunity: Regulation in obesity and metabolic disorders
- Monoclonal Gammopathy in Autoimmune Diseases: Marker, Consequence, Pathogenetic Factor—Or Coincidence?
- Suboptimal Response to Eculizumab in Renal‐Limited Thrombotic Microangiopathy Associated With Malignant Hypertension and Monoclonal Gammopathy: A Case Report
BibTeX
@article{lubkin2026corticosteroids,
title = {{Corticosteroids drive oral candidiasis by impairing type-17 immunity without inducing interferon-gammopathy}},
author = {Ashira Lubkin and Abigail Fellows and Lucas dos Santos Dias and Vasileios Oikonomou and Michail S. Lionakis},
journal = {mBio},
year = {2026},
month = oct,
doi = {10.1128/mbio.02170-26},
url = {https://journals.asm.org/doi/10.1128/mbio.02170-26},
}
RIS
TY - JOUR
TI - Corticosteroids drive oral candidiasis by impairing type-17 immunity without inducing interferon-gammopathy
AU - Ashira Lubkin
AU - Abigail Fellows
AU - Lucas dos Santos Dias
AU - Vasileios Oikonomou
AU - Michail S. Lionakis
PY - 2026
DA - 2026/10/07
JO - mBio
DO - 10.1128/mbio.02170-26
UR - https://journals.asm.org/doi/10.1128/mbio.02170-26
SN - 2150-7511
ER -